Infant Bacterial Therapeutics

44,6 SEK -4,5 %

Vær den første som følger denne virksomhed

Infant Bacterial Therapeutics, also known by the name IBT, is a pharmaceutical company. The company develops drugs to treat and prevent children from developing common ailments and diseases that occur at premature birth. Common is that disorders can occur in the development of microorganisms such as microbiome. The largest operations are in the Nordic market. The company's head office is located in Stockholm.

Omsætning

EBIT %

P/E

Udbytteafkast, %

Kursmål

Anbefaling

Opdateret

NASDAQ Stockholm

IBT B

Daglig lav / høj pris

44,6 / 50 SEK

Markedsværdi

483,84 mio. SEK

Aktieomsætning

197,13 t SEK

Volumen

4,2 t

Finanskalender

Delårsrapport

25.08.2023

Delårsrapport

10.11.2023

Viser Alle indholdstyper

Extraordinary General Meeting of Infant Bacterial Therapeutics

Selskabsmeddelelse09.06.2023

Infant Bacterial Therapeutics

Finanskalender

Extraordinary General Meeting of Infant Bacterial Therapeutics

Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics

IBT resolves on a rights issue

Annual General Meeting of Infant Bacterial Therapeutics

Infant Bacterial Therapeutics AB (publ), Interim report January 1-March 31, 2023

Notice of Annual General Meeting of Infant Bacterial Therapeutics

Infant Bacterial Therapeutics publishes Annual Report for 2022

Infant Bacterial Therapeutics’ (IBT) opening of a final infant cohort will accelerate patient recruitment

Infant Bacterial Therapeutics AB (publ) Interim report January 1- December 31, 2022

Infant Bacterial Therapeutics publishes Annual Report for 2021 in XHTML format

Infant Bacterial Therapeutics’ (IBT) publishes clinical findings in the British Journal of Gastroenterology on the convincing association of clinical events to the feeding primary endpoint of the ‘Connection Study’

IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections

Infant Bacterial Therapeutics AB (publ) (IBT), Interim Management Statement, July 1 – September 30, 2022

Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2023

Article based on Infant Bacterial Therapeutics’ (IBT) Connection Study published in the British Journal of Gastroenterology demonstrates that one day shift in Sustained Feeding Tolerance (SFT) correlates to clinically meaningful outcomes.

FDA approves Infant Bacterial Therapeutics' request for a new orphan drug designation

Infant Bacterial Therapeutics AB (publ) Interim Management Statement January 1-June 30, 2022

Infant Bacterial Therapeutics AB appoints Maria Ekdahl as CFO

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2022

Annual General Meeting of Infant Bacterial Therapeutics